Metropolitan Life Insurance Co. NY boosted its position in shares of Aptinyx Inc (NASDAQ:APTX) by 356.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,237 shares of the company’s stock after buying an additional 5,652 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Aptinyx were worth $120,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of APTX. Wells Fargo & Company MN acquired a new stake in Aptinyx during the 3rd quarter worth $185,000. Vanguard Group Inc. increased its holdings in Aptinyx by 371.0% during the 3rd quarter. Vanguard Group Inc. now owns 296,717 shares of the company’s stock worth $8,593,000 after purchasing an additional 233,717 shares in the last quarter. TIAA CREF Investment Management LLC bought a new position in Aptinyx during the 3rd quarter worth about $775,000. Bank of New York Mellon Corp bought a new position in Aptinyx during the 3rd quarter worth about $973,000. Finally, BlackRock Inc. increased its holdings in Aptinyx by 1,822.7% during the 3rd quarter. BlackRock Inc. now owns 769,072 shares of the company’s stock worth $22,272,000 after purchasing an additional 729,072 shares in the last quarter. 62.98% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on APTX shares. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Wednesday, March 27th. BMO Capital Markets reiterated an “outperform” rating on shares of Aptinyx in a report on Friday, March 22nd. Leerink Swann lowered their target price on Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, January 17th. JPMorgan Chase & Co. cut Aptinyx from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $30.00 to $8.00 in a report on Thursday, January 17th. Finally, Cantor Fitzgerald lowered their target price on Aptinyx from $18.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, March 22nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Aptinyx has a consensus rating of “Buy” and a consensus target price of $12.95.
Aptinyx (NASDAQ:APTX) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.12. The company had revenue of $1.04 million during the quarter, compared to the consensus estimate of $1.10 million. On average, sell-side analysts expect that Aptinyx Inc will post -2.11 earnings per share for the current fiscal year.
In related news, Director Robert J. Hombach acquired 25,000 shares of the firm’s stock in a transaction dated Friday, January 25th. The stock was bought at an average price of $5.53 per share, for a total transaction of $138,250.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 8.47% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/22/metropolitan-life-insurance-co-ny-boosts-holdings-in-aptinyx-inc-aptx.html.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Story: Trading Strategy Methods and Types
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.